TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Earlier diagnoses and advancements in treatment options are providing hope for patients with endometrial cancer like Yaca.

Jemperli, a cancer drug manufactured by GlaxoSmithKline, improved survival for patients diagnosed with a form of uterine cancer by more than one year, the British drugmaker said Saturday, ...

Jemperli works by attaching itself to a protein on specific immune system cells, called T cells. This helps the T cells work better to find cancer cells and kill them, which slows or stops the ...

Jemperli (dostarlimab-gxly) is a brand-name injection that’s prescribed for certain types of cancers in adults. As with other drugs, Jemperli can cause side effects, such as diarrhea, anemia ...

Jemperli in combination with chemotherapy is the first immuno-oncology treatment approved in the frontline setting for this patient population in Singapore.[1,2] Latest published local registry ...

Jemperli is a prescription drug used to treat certain cancers, including endometrial cancer. Learn about the drug's side effects and how to manage them.

PHILADELPHIA, June 03, 2024--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer ...

Jemperli (dostarlimab-gxly) is a brand-name intravenous infusion. It’s prescribed for endometrial cancer and solid tumors in certain situations. Jemperli isn’t known to interact with alcohol ...

Oct 30 (Reuters) - British drugmaker GSK , opens new tab said on Monday its cancer drug Jemperli when combined with chemotherapy, met the primary goal of overall survival in patients with advanced ...

PHILADELPHIA, August 01, 2024--Expanded approval of Jemperli (dostarlimab-gxly) plus chemo in endometrial cancer as first & only IO-based treatment to show overall survival benefit ...

GSK plc today announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center evaluating Jemperli as a first-line treatment— as ...